Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 1237

BRIEF by Amgen Inc. BENCH MEMORANDUM CLARIFYING CASE LAW CONCERNING SOURCE AND PROCESS LIMITATIONS. (Rich, Patricia) Additional attachment(s) added on 10/4/2007 (Paine, Matthew).

Download PDF
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 1237 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 1 of 6 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) AMGEN INC., ) ) Plaintiff, ) ) v. ) ) ) F. HOFFMANN-LAROCHE ) LTD., a Swiss Company, ROCHE ) DIAGNOSTICS GmbH, a German ) Company and HOFFMANN LAROCHE ) INC., a New Jersey Corporation, ) ) Defendants. ) __________________________________________) Civil Action No.: 05-12237 WGY AMGEN'S BENCH MEMORANDUM CLARIFYING CASE LAW CONCERNING SOURCE AND PROCESS LIMITATIONS Amgen respectfully submits this bench memorandum to clarify that the Court should continue to apply the case law concerning source and process limitations that this Court relied on its Markman order. In it latest bench memorandum concerning source and process limitations, Roche has attempted to circumvent that case law by pointing to the district court opinion in SmithKline v. Geneva Pharma, Inc.1 In so doing, Roche ignored the fact that Smithkline v. Apotex, the Federal Circuit opinion in the very same case as the district court decision in SmithKline v. Geneva Pharma, Inc., makes clear that process limitations may impart novel structure to a product claim and therefore serve to distinguish a product from the prior art.2 In its Markman ruling in the Roche matter, the Court recently determined that "purified from mammalian cells grown in culture" is a permissible source limitation in `422 claim 1 for 1 Docket No. 1233 at 1-2. 1 806772_1 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 2 of 6 purposes of distinguishing the claimed product over the prior art.3 In so holding, the Court properly applied SmithKline Beecham Corp. v. Apotex Corp. to reject the argument made by Roche that Lin could not distinguish the product claim in `422 claim 1 from prior art solely on the basis of a source limitation: [Roche's] argument is based on SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312 (Fed. Cir. 2006), where the Federal Circuit affirmed the invalidation of a patent to a pharmaceutical composition that recited process steps as the only distinguishing feature over a prior art tablet . . . Roche/Hoffmann's citation to SmithKline Beecham Corp. is misplaced since it omits the next passage, which recognizes that process limitations may impart novel structure to a product claim.4 Now, having already lost with its attempt to cite the Federal Circuit decision in SmithKline v. Apotex, Roche resorts to citing the district court opinion for the same proposition that the Federal Circuit opinion failed to adopt in its opinion the notion that process limitations in a product claim are not relevant to the anticipation and obviousness analysis.5 The district court's holding SmithKline v. Geneva Pharma, Inc. should only be read in light the of the Federal Circuit decision in SmithKline v. Apotex. The district court decision ignores the In re Luck on the basis that the Federal Circuit's decision in Scripps v. Genentech post-dated In re Luck.6 But the Federal Circuit's decision in Smithkline v. Apotex reaffirmed that SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1319 (Fed. Cir. 2006). Amgen, Inc. v. F. Hoffman-La Roche Ltd., 2007 WL 1893058, *7-8 (D. Mass. 2007) ("In this case, Dr. Lin has testified that at the time, `the only way [to] characterize [his claimed] product is by the way they were making ...' Def.'s Mem. Opp'n Amgen's Claim Construction. [Doc. 322] at 11-12 (citing Trial Transcript at 965:8-14, Amgen Inc. v. Hoechst Marion Roussel, Inc., 457 F.3d 1293 (Fed. Cir. 2006)). Accordingly, the Court deems it appropriate to include the "source limitation" in a product claim."). 3 4 2 Id. at *7. 5 6 Docket No. 1233. SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1323 (Fed. Cir. 2006) ("These early cases nicely illustrate the fundamentals of modern-day claim construction in light of the specification; they are not a pronouncement that it is proper to ignore process limitations in product claims. To the contrary, all of these cases state the obverse of the panel majority's view. These long-standing rules of claim construction have had many iterations, such as summarized 2 806772_1 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 3 of 6 In re Luck is valid precedent for the principle that a product different from a prior art product can be distinguished on the basis of process limitations.7 Likewise, the dissent in Smithkline v. Apotex, authored by the same judge who authored Scripps, highlights the importance of In re Luck in noting that process limitations in product-by-process claim should be given meaning. Additionally, the district court's decision in Smithkline v. Geneva Pharma, Inc. is factually distinguishable. In Smithkline v. Geneva Pharma, Inc., the district court found that process steps in the product-by-process claims did not distinguish the claimed compound over prior art compounds because the specification noted that the supposedly distinguishing properties were present in both the claimed compound and the prior art compound.8 By contrast, here, the differences between the prior art urinary EPO compounds and the claimed compound purified from mammalian cells grown in culture are documented through extensive evidence already presented in interference proceedings, where the Board of Patent Appeals and Interferences found that Fritsch failed to prove that Goldwasser's EPO and Lin's EPO were identical, and the Board noted that the outcome would have been the same even if Lin had presented none of his extensive rebuttal evidence.9 by our predecessor court in In re Luck, 476 F.2d 650, 653 (CCPA 1973), that `to the extent these process limitations distinguish the product over the prior art, they must be given the same consideration as traditional product characteristics.' That is, the process limitations cannot be ignored.") 7 SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1319 (Fed. Cir. 2006). 8 Smithkline Beecham Corp. v. Geneva Pharm., Inc., 2002 U.S. Dist. LEXIS 25275, *22 n. 14 (E.D. Pa. 2002) ("the `944 Patent specification states that the tablets of the prior art process "often" -- not always -- developed the undesirable pink hue. Id. at lines 35-36. The specification thus expressly reveals that some of the paroxetine tablets made according to the prior art wet granulation process shared the non-pink characteristic that SmithKline claims is a distinguishing property of the '944 Patent process. In other words, even considering the process limitations of the '944 Patent, it is clear that non-pink paroxetine tablets existed in the prior art.") 9 Fritsch v. Lin, 21 U.S.P.Q.2D 1739, 1742 (Bd. Pat. App. & Inter. 1991) ("Even if we had found all the evidence relied upon by Lin to have been entirely discredited by Fritsch, and we do not so find, this would have only led us to conclude that differences in average carbohydrate composition may or may not exist, i.e., that the evidence as a whole is inconclusive, and that Fritsch has not satisfied its burden of establishing that there are no differences. It is particularly telling that Fritsch has presented no affirmative evidence of its own in the form of test data to 806772_1 3 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 4 of 6 The Court should not permit Roche's attempt to mislead the Court by citing to a factually inapposite district court case that has been superseded by important Federal Circuit precedent in the very same litigation concerning the very same product-by-process claims. Roche's bench memorandum should be seen for what it is another attempt to dodge and ignore wellestablished case law allowing source and process limitations as means to distinguish a novel product that is otherwise not as easily definable using traditional product characteristics. support the assertion that r-EPO and u-EPO are identical in terms of average carbohydrate composition"). 806772_1 4 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 5 of 6 Dated: October 2, 2007 AMGEN INC., By its attorneys, Of Counsel: STUART L. WATT WENDY A. WHITEFORD MONIQUE L. CORDRAY DARRELL G. DOTSON KIMBERLIN L. MORLEY ERICA S. OLSON AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 (805) 447-5000 /s/ Patricia R. Rich D. DENNIS ALLEGRETTI (BBO#545511) MICHAEL R. GOTTFRIED (BBO#542156) PATRICIA R. RICH (BBO#640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: (857) 488-4200 Facsimile: (857) 488-4201 LLOYD R. DAY, JR. (pro hac vice) DAY CASEBEER MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: (408) 873-0110 Facsimile: (408) 873-0220 WILLIAM GAEDE III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: (650) 813-5000 Facsimile: (650) 813-5100 KEVIN M. FLOWERS (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago IL 60606 Telephone: (312) 474-6300 Facsimile: (312) 474-0448 806772_1 5 Case 1:05-cv-12237-WGY Document 1237 Filed 10/02/2007 Page 6 of 6 CERTIFICATE OF SERVICE I hereby certify that this document, filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing and paper copies will be sent to those indicated as on-registered participants. /s/ Patricia R. Rich Patricia R. Rich 806772_1 6

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?